Latest Advances in Cardiovascular and Respiratory Therapeutics
Ayma Therapeutics Inc, a privately owned IND stage company with primary office in Princeton, NJ has acquired the assets of Phaxiam, France, specifically related to former capabilities of Erytech and their red blood cell (Erycaps) technology. These assets include intellectual property (IP), hardware, software, documentation and other know-how related to encapsulation of drugs into red blood cells, testing, release and delivery to human subjects and patients in the clinic.
Since Ayma's technology is based on delivering a small molecule (Triciribine Phosphate) in red blood cell encapsulated formulation for effective delivery to target tissues involved in disease pathology for various cardiopulmonary indications, this acquisition is anticipated to directly contribute to development, testing, approval and commercialization of AYX-101, Ayma's flagship product.
As a result of this acquisition, Ayma is now poised to advance AYX-101 as a novel therapeutic using Erycaps technology and know-how that has been previously clinically validated after being successfully dosed to normal healthy volunteers (Phase I) and in patients (Phase II and III). This is a testament to strong regulatory record for Erycaps in the US and EU regions allowing Ayma to leverage this precedence and successfully initiate Phase I trial for AYX-101 in 2026.
Furthermore, this acquisition strengthens Ayma's portfolio since the combined IP provides several additional opportunities for AYX-101 in similar and other therapeutic areas either as monotherapy or in combination with approved products for the treatment of cardiopulmonary disorders including ARDS, pulmonary fibrosis and rare diseases with significant unmet needs.